Clinical Trial ProgressCapricor Therapeutics, Inc. continues to make progress in their CAP-1002 and Exosome programs.
Drug Efficacy And SafetyAntibe's lead drug, otenaproxesul, has shown strong efficacy and limited gastrointestinal side-effects in previous trials, presenting a competitive advantage in the pain management market.
Financial StabilityThe company's solid cash position is believed to be sufficient to fund the upcoming Phase II trial for otenaproxesul.